Key result
In a systematic review of 5 trials (N=205), early treatment with ACE inhibitors or ARBs may benefit dystrophinopathy, and adding eplerenone slowed the decline of left ventricular strain (P=0.020).
Why the study?
Do pharmacological interventions prevent or treat cardiac involvement in patients with Duchenne and Becker muscular dystrophy?
Population
205 participants across 5 studies; four studies included boys with Duchenne muscular dystrophy only, and one…
Comparison
Various pharmacological interventions including… vs Placebo or active comparator.
Design
Systematic_review, Included RCTs, quasi-RCTs, and randomised cross-over…
Follow-up
6 months to 3 years
Authors
Loading...
Low-certainty evidence from small trials precludes routine ACEi/ARB or eplerenone use in dystrophinopathy; larger RCTs needed.
Systematic Review (n=205)
Do pharmacological interventions prevent or treat cardiac involvement in patients with Duchenne and Becker muscular dystrophy?
Very low-certainty evidence from small trials suggests early ACEi/ARB therapy and the addition of eplerenone may help preserve cardiac function in Duchenne muscular dystrophy.
Bourke et al. (2018) conducted a systematic review in Duchenne muscular dystrophy, Becker muscular dystrophy, and X-linked dilated cardiomyopathy (n=205). ACE inhibitors, ARBs, eplerenone, idebenone, or growth hormone vs. Placebo or active control was evaluated on Change in cardiac function over six months. In a systematic review of 5 trials (N=205), early treatment with ACE inhibitors or ARBs may benefit dystrophinopathy, and adding eplerenone slowed the decline of left ventricular strain (P=0.020).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: